Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erdafitinib + abiraterone acetate
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination therapy involves the pan-fibroblast growth factor receptor (FGFR) kinase inhibitor erdafitinib (Balversa) administered in conjunction with either abiraterone acetate or enzalutamide. It is currently being evaluated in a Phase II clinical trial led by the University of Washington for the treatment of double-negative prostate cancer (DNPC). DNPC is a specific phenotype of prostate cancer characterized by the absence of androgen receptor (AR) expression and neuroendocrine markers, often associated with resistance to standard hormonal therapies. Erdafitinib works by blocking the activity of FGFR1-4 proteins, which are frequently upregulated in DNPC and contribute to tumor growth and survival. Abiraterone acetate (a CYP17 inhibitor) and enzalutamide (an AR antagonist) are standard-of-care androgen signaling inhibitors. The investigational regimen aims to determine if the addition of FGFR inhibition can provide therapeutic benefit in patients with this aggressive prostate cancer subtype.
- Brand names
- Xtandi
- Other names
- erdafitinib + enzalutamideBalversa + ZytigaBalversa + Xtandi
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR2 (Vascular endothelial growth factor receptor 2)AR (Adrenergic receptors)
Beyond the preview
Go deeper on erdafitinib + abiraterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erdafitinib + abiraterone acetate.